What is K2 MK-7 (Vitamin K2 Menaquinone-7)?
K2 MK-7 (menaquinone-7) is a highly bioavailable form of vitamin K2 that is synthesized by intestinal bacteria and found in fermented foods, playing essential roles in blood coagulation, bone mineralization, cardiovascular health, and anti-inflammatory processes.
Chemical Identity and Sources
K2 MK-7 is a member of the vitamin K family, characterized by a 2-methyl-1,4-naphthoquinone ring with a specific aliphatic side-chain structure 1. Unlike vitamin K1 (phylloquinone) found in leafy greens, K2 MK-7 is produced by intestinal bacteria including E. coli and is naturally present in fermented foods 2.
Superior Bioavailability
K2 MK-7 demonstrates significantly greater bioavailability compared to vitamin K1, with peak plasma concentrations occurring approximately 6 hours after oral intake and an exceptionally long half-life 3, 1. This superior absorption profile makes it more effective for maintaining vitamin K-dependent protein carboxylation status throughout the body 3.
Primary Biological Functions
Blood Coagulation
K2 MK-7 serves as an essential cofactor for γ-glutamyl carboxylase, the enzyme responsible for activating vitamin K-dependent clotting factors 4, 5.
Bone and Cardiovascular Health
K2 MK-7 converts undercarboxylated osteocalcin (ucOC) to its carboxylated form (cOC), facilitating calcium deposition in bones while simultaneously converting undercarboxylated matrix Gla protein (ucMGP) to cMGP, which prevents vascular calcification 1. This dual action explains its documented benefits in osteoporosis prevention and cardiovascular disease management 1, 6.
Anti-inflammatory Effects
Vitamin K2 status correlates with lower inflammatory marker concentrations, suppressing NF-κB signal transduction and reducing proinflammatory mediators including IL-1α, IL-1β, and TNF-α 2, 1.
Clinical Applications
K2 MK-7 has demonstrated health benefits in:
- Peripheral neuropathy
- Bone fracture risk reduction
- Cardiovascular health improvement
- Diabetes management
- Cognitive function (including potential Alzheimer's disease benefits)
- Cancer cell growth suppression through cell-cycle arrest and apoptosis 1, 7
Safety Profile
Vitamin K2 and K1 are not associated with toxicity 2. Animal studies established a no observed adverse effect level (NOAEL) of 10 mg/kg body weight/day in rats, with no toxicity at the limit dose of 2000 mg/kg in mice 5. The US Pharmacopeia concluded that menaquinone-7 as a dietary supplement is not associated with serious health risks 4.
Important Clinical Considerations
Anticoagulant Interactions
Patients taking vitamin K antagonists (warfarin) must avoid sudden major changes in K2 intake and require blood clotting monitoring 2. However, stable anticoagulation control is achievable through dose titration when vitamin K intake is known 2.
Measurement Limitations
Current dietary intake recommendations are established for vitamin K1 only due to insufficient data for K2 2. The adequate intake (AI) is 1 μg/kg body weight per day (EFSA) or 120 μg for males and 90 μg for females (IOM) 2.
At-Risk Populations
Measure vitamin K status in patients with fat malabsorption conditions (celiac disease, cystic fibrosis, short bowel syndrome), those on prolonged broad-spectrum antibiotics, chronic kidney disease, or anticoagulant therapy 2.